Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NVy3Z4dXS3m2b4TvfIlkKEG|c3H5 NWD5XIJ{OTBibl2= MWS3NkBp NYS3UWZGTE2VTx?= MWfQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= M133e|I1QTByOEez
HT-29 NWDr[ZlrS3m2b4TvfIlkKEG|c3H5 MknKNVAhdk1? MWC3NkBp NWLxV5NWTE2VTx?= Mn\HVI91\W62aXH0[ZMh\GmpaYTvfIlvNWmwZIXj[YQh[3m2b4TvfIlkcXS7 M2jaNVI1QTByOEez
HT-29 MYHDfZRwfG:6aXOgRZN{[Xl? NH3PfYwyOCCwTR?= NVLCblJlPzJiaB?= MUDEUXNQ NHfLSFNRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NVHJN3VVOjR7MEC4O|M>
PC3 Mn24T4lv[XOnIFHzd4F6 MUCxNFAhdk1? MkXtNUBp MYfEUXNQ Ml3pVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= M3nkWlIyQTd6Nkiz
PC3 NWfnXGFVU2mwYYPlJGF{e2G7 Mni3NVAxKG6P NHf1NG0yKGh? MnrQSG1UVw>? MVnEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NXflbmx2OjF7N{i2PFM>
PC3 NWLsSmpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS5NU42KM7:TR?= MofmNUBp M4e1WGROW09? NV\yWYpNUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N NWO5UpVrOjF7N{i2PFM>
HEK293 MYDGeY5kfGmxbjDBd5NigQ>? MlrjNVAxKG6P MUi4JIg> NXHaOJFITE2VTx?= MYXJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? NF7XdVQzOTV|OUOwNS=>
BT-20 NH[yTGlMcW6jc3WgRZN{[Xl? MoTsNlAh|ryP M3jPXGROW09? M4LFXmRw\XNibn;0JIlvcGmkaYSgcXRQWkN{IHTldIVv\GWwdDDwRYtVKFN2N{OgdIhwe3Cqb4L5cIF1cW:w MlzYNlE{PTN3NUG=
U937 Ml3QRY51cWKjY4TldolidCCDc4PhfS=> MnjIOVAh|ryP NUOx[lJPPDhiaB?= MUHEUXNQ M2nBdmlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= MkL4NlEyPDJzME[=
U937 NIm5[ZdCdnSrYnHjeIVzcWGuIFHzd4F6 MUi1NEDPxE1? MXi0PEBp NXvsVJNXTE2VTx?= NF;QZodFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| M37qcFIyOTR{MUC2
U937 NILvZnJCdnSrYnHjeIVzcWGuIFHzd4F6 M2nSU|UxKM7:TR?= NFWwT5g1QCCq Mn3ZSG1UVw>? MlfQSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> NXvW[3p6OjFzNEKxNFY>
MCF-7 MnXkRZV1d3CqYXf5JGF{e2G7 NIDPWpI{OCCwTR?= M4TXb|QhcA>? NEXpNJlFVVOR M4HxRWlv\HWlZYOgZZV1d3CqYXf5 NVW0O2ZKOjByMkixN|Q>
U87MG NWrpT49oU2mwYYPlJGF{e2G7 NXixeFVkOSEQvF2= NVX0XFl3PiCq NHraNXZFVVOR NGnVfotRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= MVWxPVg1QDRyNB?=
U87MG NYfNeXNsU2mwYYPlJGF{e2G7 M4e0XlEh|ryP NXiySJFWPiCq MkHNSG1UVw>? NFjGendRd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=> MUKxPVg1QDRyNB?=
U87MG MVHLbY5ie2ViQYPzZZk> NEjuOVAyKM7:TR?= M4O3WFYhcA>? M33OWmROW09? Mo\uSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MXOxPVg1QDRyNB?=
U87MG M1LOWWtqdmG|ZTDBd5NigQ>? M1TaNlEh|ryP NEnBV2k3KGh? MXTEUXNQ MnnaSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v MYixPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb NGDaSIxCfXSxcHjh[5khSXO|YYm= MWmwMlIh|ryP NGjLWpMzPCCq NVqzZnJkTE2VTx?= M3zCS2lv\HWlZYOgZZV1d3CqYXf5 M3W1bVE5OzlzOUS5
COS7 cells expressing EGFP-LC3 MXjBeZRweGijZ4mgRZN{[Xl? NX:4OnRmOC5{IN88US=> M4n3PVI1KGh? MmDNSG1UVw>? MlvMTY5lfWOnczDheZRweGijZ4m= NEfKem8yQDN7MUm0PS=>
H4 MYnGeY5kfGmxbjDBd5NigQ>? NEHaZ44xNjJizszN NV7WdZFZOjRiaB?= MkLHSG1UVw>? NGHuR2lKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ Ml\6NVgxOjR3OES=
HeLa NV;FbGdOTnWwY4Tpc44hSXO|YYm= NH21XIQyODBibl2= M4jsRVM3KGh? NYj6UoJSTE2VTx?= NVrJc2FvUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NHHwNW0yPzV4M{O4OS=>
HeLa MUnGeY5kfGmxbjDBd5NigQ>? M1PwXVExOCCwTR?= M3\HWFM3KGh? NF\lWGRFVVOR NX3lWJJ5UW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w M3fxcFE4PTZ|M{i1
HeLa M3SzOGZ2dmO2aX;uJGF{e2G7 MoX6NVAxKG6P NYTRfYpHOzZiaB?= NVL6W5RFTE2VTx?= MnT5TY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NXPMVlU2OTd3NkOzPFU>
SYF NX6wZWVTTnWwY4Tpc44hSXO|YYm= NW\HS2dyOTByIH7N NY\DdIM5OjRiaB?= Mnj6SG1UVw>? Mk[yTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NIjDfXQyPzV4M{O4OS=>
SYF MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O5[FExOCCwTR?= M4H2S|I1KGh? NWPodZoyTE2VTx?= Mlu5TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= MVyxO|U3OzN6NR?=
HEK293T M{HwfGFvfGm4aYLhcEBCe3OjeR?= NV6xPYFbOSCwTR?= NFHoWlc1KGR? MkHKSG1UVw>? Ml7uTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= M{noXVE4PDh3NUCx
HEK293T NW\6dZp1SW62aY\pdoFtKEG|c3H5 NITNfnYyKG6P NIHoWIE1KGR? NFXjNI5FVVOR NGfLXm1KdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> MVSxO|Q5PTVyMR?=
PBMC MmPlSpVv[3Srb36gRZN{[Xl? NXnjVIJDOSCwTR?= M13nOlE1KGR? MYLEUXNQ MljtVoVlfWOnczDDR3I2KGSnboPpeJk> Mn35NVc1QDV3MEG=
PBMC MXTGeY5kfGmxbjDBd5NigQ>? NFvZ[I0yKG6P MkPXNVQh\A>? NFr2Wo9FVVOR M2G2UWRw\XNibn;0JIFn\mWldDDDXGNTPCCmZX7zbZR6 MnHkNVc1QDV3MEG=
HEK293 cells MmDPT4lv[XOnIFHzd4F6 NFLV[oc2OCCwTR?= Mor1OFUhdWmw NHLsfHBFVVOR MnLQTY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? NGLSUIMyPzN3MEm1Ny=>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NH:2fodHfW6ldHnvckBCe3OjeR?= M1[3UVExOCCwTR?= MUC0JIg> NXnRS2s4TE2VTx?= NVfIR4QyUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NFLIb40yPzF{OEK2Ni=>
Human mixed lymphocyte NG\X[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLHOUBvVQ>? NX71SG1vTE2VTx?= NXGzTlJPUUN3ME2xMlYhdk1w Mn\GNVYyQDV6NkW=
Lewis rat lymph node cells NXfkO3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33qW|Uh|ryP Mnf4SG1UVw>? NX2wNoZmUUN3ME2yMlYh|ryP MXGxOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zyXFExKG6P MXi3NkBp MlP3SG1UVw>? M2fYSmlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= NVf1XWVJOTByMkG5OFg>
MRK-nu-1 NX74UXJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rsWGlEPTB;MD64OFUheE1? MWHTRW5ITVJ?
OCUB-M MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPIN3lKSzVyPUWuNlQheE1? Mk\mV2FPT0WU
SF539 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjWWlhKSzVyPUGxMlYheE1? NIWwdIRUSU6JRWK=
ES4 NHLYNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJzLkWgdG0> MVzTRW5ITVJ?
RL95-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v1PGlEPTB;MUC3JJBO M4\V[3NCVkeHUh?=
LC-2-ad NW\EZllrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HuW2lEPTB;NEKzJJBO NELBelVUSU6JRWK=
Daudi M1qxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjFTWM2OD12M{SgdG0> NX:5V5JNW0GQR1XS
NTERA-S-cl-D1 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jUPWlEPTB;NESzJJBO M2X3ZXNCVkeHUh?=
OS-RC-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW0WnBuUUN3ME22OVIheE1? NIjYUm5USU6JRWK=
VA-ES-BJ MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTd{MzDwUS=> MVzTRW5ITVJ?
GR-ST NU\sOG44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnGUnVlUUN3ME24OFYheE1? MVrTRW5ITVJ?
SW872 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT0Z3V1UUN3ME24OFYheE1? MXLTRW5ITVJ?
NOS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfqOXlKSzVyPUi3NUBxVQ>? NFH2VVNUSU6JRWK=
MC116 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzYTmlKSzVyPUm4OUBxVQ>? NHHLfWVUSU6JRWK=
NCI-H1355 M{C1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jlfmlEPTB;MT6wNUBvVQ>? MojLV2FPT0WU
RPMI-8226 NYDLTZR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\nTWM2OD1zLkG5JI5O M3LOWnNCVkeHUh?=
TE-15 NF;OfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFruTnNKSzVyPUGuN|Yhdk1? NVq1PFZ[W0GQR1XS
Ramos-2G6-4C10 NITYXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD0[3ZKSzVyPUGuOFYhdk1? NV7kc4R[W0GQR1XS
KU812 MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJwMEGgcm0> NHjVV4RUSU6JRWK=
EW-1 M4SyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLMWotKSzVyPUKuNVchdk1? MonyV2FPT0WU
KS-1 NITadnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnCOnFNUUN3ME2yMlQ2KG6P NXPMNXV2W0GQR1XS
SK-LMS-1 NIP2O2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DZN2lEPTB;Mj60PUBvVQ>? M{PZRXNCVkeHUh?=
TGBC1TKB MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJwNkmgcm0> MljrV2FPT0WU
TE-6 M374cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XPdGlEPTB;Mj63O{BvVQ>? NH;0TYlUSU6JRWK=
ETK-1 NX7ocGNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJwOEKgcm0> M3XlWXNCVkeHUh?=
BE-13 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJwOUmgcm0> NY\ERm9oW0GQR1XS
A3-KAW MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPrbHZKSzVyPUKuPVkhdk1? MV;TRW5ITVJ?
TE-10 NHjtXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTNwMzDuUS=> MWrTRW5ITVJ?
DOHH-2 M1XJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTNwM{Wgcm0> NXzNWnlmW0GQR1XS
ES6 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X6Z2lEPTB;Mz60N{BvVQ>? MXrTRW5ITVJ?
OPM-2 NYrvOYZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfEdGdiUUN3ME20MlE2KG6P NYfkSoRHW0GQR1XS
SH-4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn3[lZ1UUN3ME20MlM1KG6P MXfTRW5ITVJ?
NB13 NXrL[VFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYeyXlh[UUN3ME20MlM3KG6P NUP0eoZ3W0GQR1XS
HUTU-80 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTRwNEKgcm0> MVzTRW5ITVJ?
CCRF-CEM NV\zTmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzQTWM2OD12Lkm0JI5O NIDvZ5NUSU6JRWK=
TGBC24TKB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r5UmlEPTB;NT61NUBvVQ>? M4LGcHNCVkeHUh?=
697 NHToO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLUZWhKSzVyPU[uNlghdk1? NX7VXHJjW0GQR1XS
J-RT3-T3-5 M2K3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPtTWM2OD14LkS2JI5O MXXTRW5ITVJ?
KALS-1 NFzLW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHRPI94UUN3ME22MlU3KG6P NY\Kb2xzW0GQR1XS
no-10 MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zLO2lEPTB;Nz6yPUBvVQ>? MmLDV2FPT0WU
SK-NEP-1 NI[0d4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRThwN{mgcm0> NF3zUItUSU6JRWK=
L-540 NUjrWI1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7zXW9KSzVyPUGwMlQzKG6P M33ETXNCVkeHUh?=
JiyoyeP-2003 M3LXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFyLkm0JI5O MljWV2FPT0WU
HH NYLWPVA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;5SJl6UUN3ME2xNU4{QSCwTR?= Mn\QV2FPT0WU
SR MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfBZo5KSzVyPUGxMlQ2KG6P NHLxdoFUSU6JRWK=
QIMR-WIL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFzLki1JI5O MYLTRW5ITVJ?
A4-Fuk NH75R4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nDRmlEPTB;MUOuNVIhdk1? NXexeolHW0GQR1XS
CESS NE\kc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XN[mlEPTB;MUOuNVMhdk1? NH3sSohUSU6JRWK=
KE-37 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF4LkC3JI5O MmqyV2FPT0WU
SK-UT-1 NV\hVlY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF4LkixJI5O NYnlVZdEW0GQR1XS
SIG-M5 NHXVSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTMNmM3UUN3ME2xO{4zPSCwTR?= MlHhV2FPT0WU
HT MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrydnpKSzVyPUG3MlYhdk1? NE\NV|ZUSU6JRWK=
DEL MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPaNpNbUUN3ME2xO{46QSCwTR?= Ml\vV2FPT0WU
SK-PN-DW M4nqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\nTWM2OD1{MD6yN{BvVQ>? NFX4OFFUSU6JRWK=
RPMI-8402 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTJzLke3JI5O NF7wVoJUSU6JRWK=
RPMI-6666 NInNVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXoTWM2OD1{ND60NkBvVQ>? NWDZNWtvW0GQR1XS
NCI-H720 NWqxRotMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ3LkSxJI5O M1XWN3NCVkeHUh?=
EW-16 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDyR3hKSzVyPUK2Mlg4KG6P NFzscotUSU6JRWK=
BL-70 Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33DW2lEPTB;MkiuN|ghdk1? NYDT[I9MW0GQR1XS
SF126 NWG0Wok{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvSTWM2OD1|MD6zPEBvVQ>? MWrTRW5ITVJ?
BC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDJTFRKSzVyPUOxMlI3KG6P NInnWYhUSU6JRWK=
MHH-PREB-1 NIjhPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:xTWM2OD1|Mj60OEBvVQ>? MYTTRW5ITVJ?
A101D NUPqSXNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXTTWM2OD1|Mj62NkBvVQ>? MWDTRW5ITVJ?
NMC-G1 NVjQR3VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTN|Lk[3JI5O NVLSSYFrW0GQR1XS
LB1047-RCC MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;vTWM2OD1|ND62PUBvVQ>? M3nuW3NCVkeHUh?=
EM-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jM[mlEPTB;M{iuOVMhdk1? M3jqdnNCVkeHUh?=
COLO-684 NX:0elJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe4ZphKSzVyPUO5Mlghdk1? NEL3[21USU6JRWK=
Becker MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XSNGlEPTB;NEGuNFUhdk1? MYDTRW5ITVJ?
BL-41 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPK[VZKSzVyPUSzMlY3KG6P MofYV2FPT0WU
MDA-MB-134-VI NV7zZW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LX[mlEPTB;NESuNFIhdk1? MmCyV2FPT0WU
L-363 NF[0RVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXRRng3UUN3ME20OE44OyCwTR?= NEHVN|RUSU6JRWK=
ECC4 NW\BPYFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne4TWM2OD12ND63PEBvVQ>? Mk[wV2FPT0WU
A388 M{ixWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPqT|ZKSzVyPUS0MlgzKG6P MmnXV2FPT0WU
HEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEOyUFJKSzVyPUS5Mlc6KG6P M3fpWnNCVkeHUh?=
RKO NET0T2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XnV2lEPTB;NUCuNlkhdk1? MojjV2FPT0WU
KINGS-1 NVrMZYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfkcYRmUUN3ME21NU42PSCwTR?= MULTRW5ITVJ?
EB-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTV{Lk[3JI5O MYTTRW5ITVJ?
ARH-77 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTaRnJKSzVyPUWyMlghdk1? M1nEWnNCVkeHUh?=
GCIY MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[zdGlEPTB;NUOuOFYhdk1? M4jaT3NCVkeHUh?=
NCI-H1304 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7FN4pKSzVyPUW3MlIzKG6P MWTTRW5ITVJ?
KARPAS-299 NXPwZ2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDL[GlKSzVyPU[xMlgzKG6P MYnTRW5ITVJ?
IA-LM MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWyZ3BKSzVyPU[4MlE{KG6P NYO3N3hRW0GQR1XS
GI-1 M1XEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fQfmlEPTB;N{CuN|khdk1? MYTTRW5ITVJ?
TE-11 NXnaOFdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTd5LkG3JI5O NXPKe|Q3W0GQR1XS
LS-411N M3;IUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;yZ2xKSzVyPUe3MlU4KG6P MYHTRW5ITVJ?
no-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLmUGJKSzVyPUizMlI1KG6P MnHuV2FPT0WU
MV-4-11 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLWTWM2OD16Mz63N{BvVQ>? NXX6TphvW0GQR1XS
BV-173 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTh|Lkm3JI5O M3PNRnNCVkeHUh?=
CMK NITDblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1izUmlEPTB;OESuNVYhdk1? MnnxV2FPT0WU
LC4-1 M2f2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XhUmlEPTB;OE[uO|Ihdk1? NWrVbYE3W0GQR1XS
COR-L279 NELnNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDjTWM2OD16Nz6yOUBvVQ>? NFTQdmRUSU6JRWK=
NCI-H209 NVntUnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe0[ldKSzVyPUi3MlQyKG6P NHPyfmNUSU6JRWK=
Raji M3HxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHNTWM2OD16OT63NkBvVQ>? M1rCRXNCVkeHUh?=
LB996-RCC Mn;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTl|LkSzJI5O NV3qTZV5W0GQR1XS
NCI-H526 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;wN|Y2UUN3ME25N{42QSCwTR?= NEflWFRUSU6JRWK=
KGN MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTl4LkK5JI5O NFLXd3FUSU6JRWK=
MOLT-4 M4[3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PNbGlEPTB;OU[uO|khdk1? MUjTRW5ITVJ?
PF-382 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LP[mlEPTB;OU[uO|khdk1? M13hZ3NCVkeHUh?=
BC-3 NVvsdWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHmTWM2OD17OT6xPEBvVQ>? NX74OVNjW0GQR1XS
KARPAS-422 MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrVXoZKSzVyPUGwNk4xQSCwTR?= NEnlN2xUSU6JRWK=
SBC-1 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOxZmJKSzVyPUGwO{44PSCwTR?= M4iyVHNCVkeHUh?=
LC-1F NV;Fd|VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fTOmlEPTB;MUC4MlA2KG6P NVrPVFRkW0GQR1XS
GB-1 M3vsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXmfYNSUUN3ME2xNFkvODJibl2= MWnTRW5ITVJ?
SNB75 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjEXG1KSzVyPUGxPU43QSCwTR?= MlfIV2FPT0WU
BB65-RCC MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXCTpE1UUN3ME2xNVkvQTNibl2= MonRV2FPT0WU
NCI-N87 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PwcGlEPTB;MUKxMlk5KG6P M1PWbHNCVkeHUh?=
IST-MEL1 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF{Mj6zPEBvVQ>? Mmi1V2FPT0WU
HOP-62 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\GWmlEPTB;MUK2Mlg6KG6P NEfnWIFUSU6JRWK=
ACN MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF2Nj63OUBvVQ>? NHX6TYVUSU6JRWK=
DMS-114 M2DZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjBb5RsUUN3ME2xOVAvPjdibl2= Mne2V2FPT0WU
MLMA MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe2UnBKSzVyPUG1PU45QCCwTR?= M1[3bnNCVkeHUh?=
HT-144 NXfMfWRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm3TWM2OD1zNkWuOFMhdk1? Mn3IV2FPT0WU
C2BBe1 NVP0dnFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HEcGlEPTB;MU[3Mlc3KG6P MXzTRW5ITVJ?
L-428 NYrjTHR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nW[mlEPTB;MUe3Mlchdk1? MUHTRW5ITVJ?
DU-4475 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[4OXVKSzVyPUG4O{43QCCwTR?= NYDRWHdsW0GQR1XS
CP67-MEL NHvPc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\zTWM2OD1zOUmuN|ghdk1? MVLTRW5ITVJ?
MEG-01 M331bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH2PWYxUUN3ME2yNFEvQTZibl2= Mn3IV2FPT0WU
IST-SL2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJyOD62N{BvVQ>? NEHCNHpUSU6JRWK=
ES8 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnFTWM2OD1{MkWuPVQhdk1? MUjTRW5ITVJ?
COLO-800 NWP5T2tCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfmPIlKSzVyPUKzOU4zQCCwTR?= MWPTRW5ITVJ?
MFH-ino NHvMNWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJ|NT64OEBvVQ>? NVL6e2VYW0GQR1XS
OVCAR-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ|Nz6yOEBvVQ>? NIDGSJZUSU6JRWK=
PSN1 NEfEd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ2Mj63NUBvVQ>? NIr0WWRUSU6JRWK=
EW-12 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6zTWM2OD1{NEOuNUBvVQ>? MUjTRW5ITVJ?
HCC1599 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDWNGZKSzVyPUK2NU41PyCwTR?= M4PzZXNCVkeHUh?=
SJSA-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr5TXF5UUN3ME2yO|EvPDZibl2= NHq2ZY5USU6JRWK=
ST486 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu0Om9KSzVyPUK5Ok4yPCCwTR?= M1fpbHNCVkeHUh?=
NOMO-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjrTWM2OD1|MECuNlEhdk1? NWHoOIU4W0GQR1XS
MN-60 NYTNfpNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTNyNT6zNkBvVQ>? NWHq[|JOW0GQR1XS
HCC1187 NGLwOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnEWoZQUUN3ME2zNFcvOjVibl2= MoDlV2FPT0WU
SW982 NE\X[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPETWM2OD1|MUSuO|Uhdk1? NFm1PZBUSU6JRWK=
LB647-SCLC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrZTWM2OD1|MkiuO|Ehdk1? M{PGd3NCVkeHUh?=
HC-1 NU\ue3VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN|NT61JI5O MWnTRW5ITVJ?
EHEB NHOzXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfJeo5KSzVyPUOzO{42OiCwTR?= MYrTRW5ITVJ?
TUR MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfKVFVnUUN3ME2zOlMvQTVibl2= NYn5ZpdbW0GQR1XS
LU-139 M{X3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvERZBZUUN3ME2zO|gvODJibl2= NGn0[ZlUSU6JRWK=
NB1 MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fwR2lEPTB;M{i0MlQ2KG6P MYPTRW5ITVJ?
BB30-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTN6OD6zNkBvVQ>? M4C1bnNCVkeHUh?=
HAL-01 Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnnTWM2OD1|OEmuNlYhdk1? M4\FN3NCVkeHUh?=
K5 NXvqRnl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRzMT6zO{BvVQ>? MYPTRW5ITVJ?
MZ2-MEL MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzVdolKSzVyPUSxN{43PCCwTR?= NVmyOINKW0GQR1XS
RXF393 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDEbGFKSzVyPUSxOk41PSCwTR?= MnLjV2FPT0WU
NCI-H1648 Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnoZXJIUUN3ME20NVcvPTNibl2= MnPwV2FPT0WU
TE-12 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnGWW1KUUN3ME20N|QvOjZibl2= M2PNfHNCVkeHUh?=
EoL-1- NYm1R5dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLyTWM2OD12M{euPVghdk1? MUHTRW5ITVJ?
JAR MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki1TWM2OD12M{iuOlIhdk1? M{fTbXNCVkeHUh?=
DSH1 NV\yZng4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KwbGlEPTB;NEW4MlkyKG6P MUnTRW5ITVJ?
NCI-H187 NHL0OlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nNfmlEPTB;NE[yMlgyKG6P MU\TRW5ITVJ?
HCE-4 M{fodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHZeWFKSzVyPUS3O{43PiCwTR?= NHTieZBUSU6JRWK=
8-MG-BA MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTtXJBFUUN3ME21PFEvPTJibl2= NV:2XIpxW0GQR1XS
KLE MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTV6NT6yJI5O NIrxXIZUSU6JRWK=
KNS-42 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHRT|I1UUN3ME21PFYvQDFibl2= M2\zRnNCVkeHUh?=
MSTO-211H NH\ldnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfHNFlKSzVyPU[wPU44PCCwTR?= Mmn1V2FPT0WU
GDM-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHVT5pKSzVyPU[xOE4xQSCwTR?= NH7JRoFUSU6JRWK=
TE-1 NUjGR3hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfDV2VKSzVyPU[0Ok4yOiCwTR?= MX;TRW5ITVJ?
BT-474 M{PHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTZ2Nz6wOkBvVQ>? MY\TRW5ITVJ?
KARPAS-45 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrMVmE3UUN3ME22OFcvPiCwTR?= NF3ObINUSU6JRWK=
MOLT-16 M3q4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjoZXM1UUN3ME22OFcvQTNibl2= NVnpSIxoW0GQR1XS
KURAMOCHI NF2xS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPDe2lKSzVyPU[1O{42OSCwTR?= NWHJRXV5W0GQR1XS
K-562 NVrKeWpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTZ4OT61NUBvVQ>? NWPCTWE5W0GQR1XS
EKVX NWTIVIlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTZ5Mj63NUBvVQ>? M1TaVHNCVkeHUh?=
GAK NEnRe|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmyTWM2OD14N{WuN{BvVQ>? M{[2[3NCVkeHUh?=
NCI-SNU-5 NIG5Z|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzjTWM2OD14OUCuNFEhdk1? NYXiZoZ5W0GQR1XS
NCI-H2126 NFHZSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv5W4V{UUN3ME23NlYvQDdibl2= MWPTRW5ITVJ?
CTV-1 M4fwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTd2ND65JI5O MUHTRW5ITVJ?
SW962 MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XsO2lEPTB;N{S4MlQ1KG6P NUDpS49XW0GQR1XS
MONO-MAC-6 NFfBZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGWxXXRKSzVyPUe1Ok46OyCwTR?= MlfKV2FPT0WU
NCI-H748 NFLidWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTd3OD65PUBvVQ>? MkTuV2FPT0WU
NCI-H524 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnS[ZhqUUN3ME23PFAvPzNibl2= NYTPO5J{W0GQR1XS
LS-123 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf2TWM2OD15OUWuOlkhdk1? M2rVfXNCVkeHUh?=
NB7 MnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXJfZN{UUN3ME24NVQvOTRibl2= M1PyXnNCVkeHUh?=
LS-1034 MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPsb3RTUUN3ME24NlgvQThibl2= NX\mOGY1W0GQR1XS
TE-5 M37VSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHr2clJKSzVyPUi4N{42PiCwTR?= NXnmfIxuW0GQR1XS
A704 M4n2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrscIZFUUN3ME24PVkvOTVibl2= NEn4O41USU6JRWK=
TK10 NVH1[m9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWryUJFnUUN3ME25NVYvODNibl2= NH3jO21USU6JRWK=
NCI-H345 NF2wbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLiTWM2OD17NEOuNlIhdk1? M3XuXXNCVkeHUh?=
CGTH-W-1 M4\kR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPkWYRKSzVyPUm0PE4yOyCwTR?= NUO4dYZEW0GQR1XS
NCI-H510A NFPGTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTl6NT6xNkBvVQ>? MlzqV2FPT0WU
NCI-H1963 NELxZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DBRWlEPTB;MT6wN|I6OiEQvF2= NYX0d|V2W0GQR1XS
SCC-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjOTWM2OD1zLkCzOFE1KM7:TR?= NYfpT4p6W0GQR1XS
EW-11 NFey[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwMEi3OFMh|ryP NFHXOmZUSU6JRWK=
CPC-N NUT4fWk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLXTWM2OD1zLkC4PEDPxE1? Mk\wV2FPT0WU
NCI-H1417 NULiW3FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwMUKyOkDPxE1? MVnTRW5ITVJ?
DG-75 NX7kPJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXtN|FDUUN3ME2xMlE3Ojh3IN88US=> MnjvV2FPT0WU
HD-MY-Z NYXpRpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMU[0NVYh|ryP M{LkT3NCVkeHUh?=
ATN-1 NX\RXWRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\xTWM2OD1zLkK2NlA6KM7:TR?= NGnIZolUSU6JRWK=
KM-H2 NHjqT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwMk[0NFgh|ryP MUPTRW5ITVJ?
NCI-H2081 NV3LO4FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOwflFKSzVyPUGuNlY3OzdizszN MYPTRW5ITVJ?
HL-60 NEfiZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnRcmtKSzVyPUGuNlY6PTlizszN NYnheJVjW0GQR1XS
DB MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwMkeyOFIh|ryP Ml[yV2FPT0WU
NCI-H1522 M{LXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LVZmlEPTB;MT6yPFg5PyEQvF2= MoXtV2FPT0WU
AM-38 NELNXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HIVGlEPTB;MT6zNFczKM7:TR?= NUDB[JhJW0GQR1XS
NCI-H446 NH36dohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwM{KxNlEh|ryP MXLTRW5ITVJ?
SU-DHL-1 NYjsXIxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DDUmlEPTB;MT6zNlgxOSEQvF2= MVTTRW5ITVJ?
NH-12 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwM{[zO|Qh|ryP MnvSV2FPT0WU
DMS-79 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFwM{[4OlYh|ryP NFy3SGJUSU6JRWK=
NCI-H716 MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTFwM{i5PFYh|ryP NFnMV|dUSU6JRWK=
ML-2 M17EVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u3NmlEPTB;MT60NVUzQSEQvF2= NE\jUHRUSU6JRWK=
NB10 NUnTXndxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwNE[2N|Ih|ryP MXPTRW5ITVJ?
ONS-76 M{TOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnyPY56UUN3ME2xMlU{PTZ7IN88US=> M2PCb3NCVkeHUh?=
LOUCY M4nrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D3[WlEPTB;MT61OFY2PyEQvF2= NXyzS5d5W0GQR1XS
SCLC-21H M1:1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHpRmdKSzVyPUGuOVg2QDJizszN MlzPV2FPT0WU
TGW Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LzUGlEPTB;MT62N|k4PSEQvF2= NEC5Z2NUSU6JRWK=
LXF-289 M{TReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTFwN{OyOlgh|ryP MlHSV2FPT0WU
BB49-HNC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrlTWM2OD1zLkezOVg3KM7:TR?= MoLvV2FPT0WU
NCI-H747 NWLJXmNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XlU2lEPTB;MT63OVM1PiEQvF2= NHnYbJlUSU6JRWK=
LU-165 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCzNmNjUUN3ME2xMlg1QTh4IN88US=> M3jmUHNCVkeHUh?=
OMC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK1RZpKSzVyPUGuPVUxPjZizszN M{LEPHNCVkeHUh?=
RCC10RGB MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fIcWlEPTB;MT65OVgyPyEQvF2= MljvV2FPT0WU
SW684 NEjqe2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInYcIZKSzVyPUGuPVYxQTlizszN M4fzRXNCVkeHUh?=
TE-8 MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwMEW1OVkh|ryP MX;TRW5ITVJ?
SK-N-DZ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq5TWM2OD1{LkGzNlc1KM7:TR?= MYTTRW5ITVJ?
EVSA-T MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fBO2lEPTB;Mj6xO|MyPSEQvF2= MnK3V2FPT0WU
KASUMI-1 NXjRS4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LES2lEPTB;Mj6xPFgyPSEQvF2= MUDTRW5ITVJ?
NKM-1 M{XTWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrFXldXUUN3ME2yMlI2PDd{IN88US=> MULTRW5ITVJ?
CAL-148 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX3WldKSzVyPUKuN|M3OTRizszN NEDE[4RUSU6JRWK=
NCI-H64 NHflVZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPkTWM2OD1{LkO0NlMzKM7:TR?= NWftWmM5W0GQR1XS
KNS-81-FD MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS2copKSzVyPUKuN|Y3OiEQvF2= M2rRO3NCVkeHUh?=
KM12 NHLtV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzoTWM2OD1{LkSwPFM6KM7:TR?= MkLxV2FPT0WU
SW954 NHvYdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwNEe3O|kh|ryP MnvzV2FPT0WU
NCI-H1395 NYrZWVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPMTWM2OD1{LkWyOlQ2KM7:TR?= MVTTRW5ITVJ?
DJM-1 M1r1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;6d2lEPTB;Mj62NFY{KM7:TR?= MnzEV2FPT0WU
COLO-668 MnvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3TTWM2OD1{LkiyOlk2KM7:TR?= MWjTRW5ITVJ?
NCI-H1436 M3PoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTrTWM2OD1{Lki1OlE2KM7:TR?= MoTnV2FPT0WU
LB2241-RCC MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPUTWM2OD1{Lki2PFM6KM7:TR?= NH7UUohUSU6JRWK=
GT3TKB NF21doFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJwOEmwOVUh|ryP NGjGWnBUSU6JRWK=
COLO-824 NEPiOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PaXmlEPTB;Mj64PVc3QCEQvF2= MWLTRW5ITVJ?
ES1 MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3XOFlZUUN3ME2yMlg6QDd7IN88US=> MkTYV2FPT0WU
LB771-HNC MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\KTWM2OD1{LkmwPVQ3KM7:TR?= MnLrV2FPT0WU
GI-ME-N M{\uZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPITWM2OD1|LkCwPVA1KM7:TR?= NIn2XY1USU6JRWK=
NALM-6 MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP2PGJKSzVyPUOuNFA6OzNizszN MnH5V2FPT0WU
LU-134-A M1Trfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\kOVM{UUN3ME2zMlA2PDJ3IN88US=> NWXzOm9XW0GQR1XS
DMS-153 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTNwMEW4NlQh|ryP NEjvTFVUSU6JRWK=
MZ1-PC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP1R4tGUUN3ME2zMlA6ODd6IN88US=> NIDFSWFUSU6JRWK=
NCI-H1155 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULa[YNCUUN3ME2zMlEyPjFizszN MkXhV2FPT0WU
CAS-1 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXHcIFKSzVyPUOuNVM4ODdizszN NVnXRWIyW0GQR1XS
D-502MG MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[1OFdKSzVyPUOuNVQ{QSEQvF2= NWrPco5VW0GQR1XS
NCI-H2141 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLjWldKSzVyPUOuNVc1PTJizszN NHfiO4hUSU6JRWK=
NB6 M3LHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj3PY5KSzVyPUOuNVgzPTlizszN NWC0UoE4W0GQR1XS
NCCIT MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv6WVd2UUN3ME2zMlIyQDB7IN88US=> MWDTRW5ITVJ?
NB69 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjyTm5KSzVyPUOuN|E5QTFizszN NILtZ4xUSU6JRWK=
JVM-2 M3LFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTNwM{[0N|Mh|ryP M4P0SXNCVkeHUh?=
K052 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL6eW1KSzVyPUOuN|c6PjhizszN NGrZ[llUSU6JRWK=
HCC2157 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHLcIFKSzVyPUOuOVMzOjhizszN NFfCRXNUSU6JRWK=
KMOE-2 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vDNmlEPTB;Mz61OFI1OiEQvF2= NETpSFFUSU6JRWK=
SF268 Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[zc2dKSzVyPUOuO|E2PTRizszN NXfPW3RMW0GQR1XS
CHP-126 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MortTWM2OD1|Lke2OFU5KM7:TR?= NEDufmhUSU6JRWK=
CP66-MEL MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTBSGlKSzVyPUOuO|kxQTRizszN MkPFV2FPT0WU
NCI-H69 NX7wdIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TiTmlEPTB;ND6wNVk{PiEQvF2= NIPaOZFUSU6JRWK=
A253 NYTGSnBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXwS3VKSzVyPUSuNFIyODFizszN MVvTRW5ITVJ?
NB14 NG\Pc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LPcWlEPTB;ND6xNFQ4QSEQvF2= NWL1e5J[W0GQR1XS
NCI-H1694 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLsepRQUUN3ME20MlE{OTF{IN88US=> M4rLR3NCVkeHUh?=
NCI-H2196 M3TnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T5PGlEPTB;ND6xO|E3QSEQvF2= M1zYTHNCVkeHUh?=
TE-9 M1HDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;zNnlKSzVyPUSuNVc2QDJizszN NXWwcI9bW0GQR1XS
D-283MED MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK3TWM2OD12LkG4PFQh|ryP NHuxeWpUSU6JRWK=
OCI-AML2 NUPHXGVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu1[2RKSzVyPUSuNVk1QDlizszN NVTCclR2W0GQR1XS
D-263MG Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[1dYxKSzVyPUSuNlI6PjFizszN MYrTRW5ITVJ?
MPP-89 NFOzd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe0[XJEUUN3ME20MlI4OzB2IN88US=> MmDmV2FPT0WU
LAMA-84 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXuXGxkUUN3ME20MlMxPDJzIN88US=> NEHMbFBUSU6JRWK=
LB373-MEL-D MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInmPYRKSzVyPUSuN|Y4QDlizszN NFvpVnRUSU6JRWK=
UACC-257 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\2TWM2OD12LkO5OVM1KM7:TR?= NXTLeGtpW0GQR1XS
MC-CAR MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfFUlRbUUN3ME20MlQ{QTlizszN M{ntd3NCVkeHUh?=
COLO-320-HSR NHHJfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTRwNES0Nlch|ryP MVfTRW5ITVJ?
P30-OHK MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTDTWM2OD12Lk[2OVgyKM7:TR?= NVWweYFsW0GQR1XS
UACC-812 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTRwNkmxOlEh|ryP NWq4[lk{W0GQR1XS
CTB-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLWPWpKSzVyPUSuO|E2PTVizszN MoTnV2FPT0WU
ALL-PO NHfSZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRwOESwO|ch|ryP NIDaelJUSU6JRWK=
SK-MEL-2 M3[3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXueo95UUN3ME20Mlg3QTV3IN88US=> MVrTRW5ITVJ?
TC-YIK MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm3SpdHUUN3ME20Mlk4QTR{IN88US=> M2f1NnNCVkeHUh?=
NCI-H1882 M4XYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke1TWM2OD13LkCyNFAyKM7:TR?= MkjoV2FPT0WU
MHH-CALL-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn1bVZKSzVyPUWuNFUxPDJizszN MmjXV2FPT0WU
U-87-MG NXL3TJFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrhN4ZzUUN3ME21MlA6PDZ4IN88US=> NUfxd49kW0GQR1XS
NCI-H1092 NXTPTGRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPYV2NpUUN3ME21MlI3PTV3IN88US=> NUHnO4t1W0GQR1XS
TE-441-T MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HUZ2lEPTB;NT6yO|gzKM7:TR?= NUixU2d7W0GQR1XS
SK-MEL-1 NX20c3VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTVwMkmwOFQh|ryP M4TnWHNCVkeHUh?=
EW-22 NIH0bopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;PTWM2OD13LkK5OFY3KM7:TR?= MWTTRW5ITVJ?
MZ7-mel Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj5elFKSzVyPUWuOFA3QTFizszN MmXMV2FPT0WU
LP-1 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS2TWM2OD13LkSxNlkyKM7:TR?= NELoOnhUSU6JRWK=
NCI-SNU-16 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTVwNkSwO|Qh|ryP MY\TRW5ITVJ?
LU-65 M1XrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTVwN{[zO|Mh|ryP NEfzd5FUSU6JRWK=
CW-2 M{XY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPCWpRKSzVyPUWuPFU6PTlizszN NEHZNGdUSU6JRWK=
WSU-NHL MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLxSVRDUUN3ME21Mlk2OTd2IN88US=> NV20TmJoW0GQR1XS
IST-MES1 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTVwOUW0OFMh|ryP NWf5Tm1jW0GQR1XS
U-266 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPD[2dxUUN3ME21Mlk5OjB{IN88US=> M4DQeHNCVkeHUh?=
TALL-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTZwMUS2PFgh|ryP MVLTRW5ITVJ?
Calu-6 NGXvb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vwTWlEPTB;Nj6xOVMyPiEQvF2= MW\TRW5ITVJ?
MMAC-SF MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7ZS3pKSzVyPU[uNVg2PTZizszN MnzUV2FPT0WU
NCI-H82 NF7SOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G0e2lEPTB;Nj6yNFQ5QSEQvF2= NIfLbFZUSU6JRWK=
RS4-11 NFq5ToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHNWYFKSzVyPU[uNlU5QTdizszN NU\iSId2W0GQR1XS
SNU-C2B M4OweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnXN|ZuUUN3ME22MlQxQTZ7IN88US=> Mnm3V2FPT0WU
BOKU MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfDWWVQUUN3ME22MlQ4PTl5IN88US=> NI\XeZNUSU6JRWK=
C8166 M4XrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTZwNUW5NVIh|ryP MnyzV2FPT0WU
D-247MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTdwMESzOFch|ryP NGTZO4VUSU6JRWK=
EW-18 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTdwMEeyPVIh|ryP NFLmeHBUSU6JRWK=
KG-1 NYDMVoRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHFTnNKSzVyPUeuOlI4OzhizszN NEDqZYJUSU6JRWK=
REH NH[wS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjuTWM2OD15Lk[4NVA6KM7:TR?= Ml7kV2FPT0WU
U-698-M MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvTd|BsUUN3ME23Mlg1OzF3IN88US=> M3fmUXNCVkeHUh?=
KP-N-RT-BM-1 M3zNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTdwOUOwNlkh|ryP M3rFfXNCVkeHUh?=
MS-1 NWn5cWV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7JTWM2OD15Lkm2NFQyKM7:TR?= NHH4[opUSU6JRWK=
SNU-C1 M{f5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHkTWM2OD15Lkm4NVkzKM7:TR?= M{DUVHNCVkeHUh?=
SK-MM-2 M2\kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm5PXU6UUN3ME24MlI3ODZ3IN88US=> NYjid5dDW0GQR1XS
LAN-6 NHrjcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvUTWM2OD16LkOwNFAyKM7:TR?= MnvMV2FPT0WU
NEC8 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLST4RKSzVyPUiuN|A3QTFizszN MnH2V2FPT0WU
NCI-H1770 NUjwW21nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3ZblZKSzVyPUiuN|gxODJizszN Mm\BV2FPT0WU
D-336MG NEjIO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRThwNECxNVYh|ryP NXHnVGF6W0GQR1XS
COLO-829 MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjOZ3VKSzVyPUiuOFg5PzlizszN NI\WT5VUSU6JRWK=
LS-513 M3y0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULDTHFEUUN3ME24MlU6PTl7IN88US=> MoK3V2FPT0WU
YT M2fVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2roeWlEPTB;OD62NlQzPyEQvF2= NGnGdldUSU6JRWK=
EW-24 NUPDXJJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRThwN{[1OEDPxE1? MUXTRW5ITVJ?
IST-SL1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7JOoNKSzVyPUiuPFY2PDNizszN NIXzfHRUSU6JRWK=
CA46 NICyZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRThwOUWwPVgh|ryP MXHTRW5ITVJ?
NCI-H1838 M1HKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XQTmlEPTB;OD65PFYxOiEQvF2= MXjTRW5ITVJ?
NCI-H719 NHHkcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TDSGlEPTB;OT6yOVI4QSEQvF2= MkPyV2FPT0WU
HCE-T M2HxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GwWWlEPTB;OT6zNFg2OSEQvF2= NHrwcGRUSU6JRWK=
A498 M1rx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLjTWM2OD17LkO2NVI1KM7:TR?= MWHTRW5ITVJ?
LB831-BLC NV\aWHU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTlwN{[1NlEh|ryP NUDQXmUyW0GQR1XS
SKM-1 M4XIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LqZWlEPTB;OT64OVk3OyEQvF2= MXjTRW5ITVJ?
THP-1 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTlwOU[5NVgh|ryP M4f6OHNCVkeHUh?=
SHP-77 NETzb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDEW4VKSzVyPUGwMlQxPyEQvF2= MmroV2FPT0WU
EW-3 NG\XcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XVcWlEPTB;MUCuOlI5QSEQvF2= NFm1VmRUSU6JRWK=
KY821 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnKW4JKSzVyPUGwMlc3OyEQvF2= NFW1[ZJUSU6JRWK=
NCI-SNU-1 NYXhfXkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlqyTWM2OD1zMT6wNlE4KM7:TR?= M1fVZ3NCVkeHUh?=
HCC2218 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFzLkO5PFYh|ryP NHXyO4pUSU6JRWK=
IM-9 Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[5UYFKSzVyPUGxMlUyODZizszN NHrIWFJUSU6JRWK=
NCI-H889 M3HFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTFzLkWzNVMh|ryP MWnTRW5ITVJ?
HDLM-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF{LkSxOVkh|ryP NUW4TlhsW0GQR1XS
LB2518-MEL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3HendKSzVyPUGyMlY5OTVizszN MlP2V2FPT0WU
NCI-H23 MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF|LkK0NlUh|ryP MVnTRW5ITVJ?
NB17 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF|LkS1O|kh|ryP M{[xc3NCVkeHUh?=
NCI-H322M NG\INFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\PdVlKSzVyPUG0MlQxPjhizszN MWHTRW5ITVJ?
SUP-T1 M2XEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nNcmlEPTB;MUSuOFE{KM7:TR?= MVjTRW5ITVJ?
ES3 MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXxVHdKSzVyPUG1MlA4ODNizszN NVnxTHNEW0GQR1XS
ES5 Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF31T4RKSzVyPUG1MlA4QDdizszN NYT3fpdrW0GQR1XS
NCI-H1650 NIjOellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[1TWM2OD1zNT60PVc6KM7:TR?= M4LxbXNCVkeHUh?=
NCI-H226 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3npU2lEPTB;MUWuPFc3QCEQvF2= NITtdZBUSU6JRWK=
COR-L88 M1Pie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTF4LkOxOEDPxE1? M1fjb3NCVkeHUh?=
SCC-15 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fIPWlEPTB;MU[uN|g3QSEQvF2= M{XMOnNCVkeHUh?=
GOTO MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\pWlFKSzVyPUG2MlQ4QTNizszN MWjTRW5ITVJ?
SIMA NEHOU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF4LkS4NFIh|ryP MmnIV2FPT0WU
NCI-H1299 NYft[YNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF5LkG1PVEh|ryP MlHNV2FPT0WU
NCI-H1581 NVzQOZlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfQPW1KSzVyPUG3MlQzOTlizszN NGfEUItUSU6JRWK=
MHH-NB-11 NYPxRXRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG1TWM2OD1zNz65Olg{KM7:TR?= MWDTRW5ITVJ?
MFM-223 MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITDdIVKSzVyPUG4MlA2OzhizszN MoDTV2FPT0WU
ES7 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfUPWt2UUN3ME2xPE42PDNzIN88US=> NFnkT5NUSU6JRWK=
JVM-3 M4jmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi5ZXpZUUN3ME2xPE44OTdizszN NITmepdUSU6JRWK=
RL M1H4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJyLkO4PEDPxE1? MkW4V2FPT0WU
EC-GI-10 NGm1bXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HleGlEPTB;MkGuNlA1OSEQvF2= MnHaV2FPT0WU
LNCaP-Clone-FGC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlGzTWM2OD1{MT62O|Y5KM7:TR?= NV3xUogyW0GQR1XS
IMR-5 M{fWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW5TWM2OD1{MT64OFk1KM7:TR?= M{D1bXNCVkeHUh?=
KP-N-YS M{\GRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJzLki3OUDPxE1? MUjTRW5ITVJ?
Mo-T NHvRSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zCV2lEPTB;MkKuNlE5PSEQvF2= NFjXSHlUSU6JRWK=
NCI-H128 NGDUNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHJTWM2OD1{Mz61PFU{KM7:TR?= M{m3OXNCVkeHUh?=
RH-1 M{LUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\5TWM2OD1{Mz63PFY3KM7:TR?= M4D1T3NCVkeHUh?=
NCI-H2171 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXOTWM2OD1{ND6yOFg2KM7:TR?= MYLTRW5ITVJ?
RPMI-8866 M2fGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWyfZJWUUN3ME2yOk44PDJizszN MkfSV2FPT0WU
SK-N-FI NUOwN2IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJ5LkO4NVEh|ryP M{HrNXNCVkeHUh?=
LOXIMVI NV\5Z41{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\vTWM2OD1{Nz64NFUyKM7:TR?= NXHCeGJ2W0GQR1XS
P31-FUJ NYDoNYZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmwS3g5UUN3ME2zNU42Ozd2IN88US=> MlXxV2FPT0WU
KMS-12-PE M3HsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETmRlVKSzVyPUS5MlU{ODJizszN NHP3TIdUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay
+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research
+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02240407 Not yet recruiting Pompe Disease University of Florida October 2016 Phase 1
NCT02793544 Not yet recruiting Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma|Acute Myelogenous Leukemia (AML)|Acute Biphenotypic Leukemia (ABL)|Acute Undifferentiated Leukemia (AUL) Center for International Blood and Marrow Transplant Research|National Marrow Donor Program|Resource for Clinical Investigation in Blood and Marrow Transplantation August 2016 Phase 2
NCT02587325 Not yet recruiting Pulmonary Hypertension Aadi, LLC August 2016 Phase 1
NCT02806947 Not yet recruiting Acute GVHD Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program July 2016 Phase 2
NCT02833506 Not yet recruiting Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer Roswell Park Cancer Institute|National Cancer Institute (NCI) July 2016 Phase 1
NCT02844270 Not yet recruiting Heart Diseases Shanghai Bio-heart Biological Technology Co., Ltd. July 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID